More than $1 billion has been wiped off the value of Mesoblast since Monday as rattled investors dumped shares on fears the US healthcare regulator would reject its application to market a drug to treat transplant rejections in children.
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
Tom Richardson was a journalist at The Australian Financial Review
